Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram

Neuropsychopharmacology

Volumn 22, Issue 5, 2000, Pages 513-521

  Liechti, Matthias E ^a   Baumann, Christine ^a   Gamma, Alex ^a   Vollenweider, Franz X ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

3,4 Methylenedioxymethamphetamine; Citalopram; Ecstasy; MDMA; Psychological effects; Selective serotonin reuptake inhibitors; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EMOTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL PERFORMANCE; MOOD; NORMAL HUMAN; PERCEPTION; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; SEROTONIN RELEASE; VOLUNTEER;

ADULT; AMPHETAMINE-RELATED DISORDERS; BRAIN; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0034061432     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00148-7     Document Type: Article

References (50)

1. Battaglia G., Brooks B.P., Kulsakdinum C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol. 149:1988;159-163.
2. Battaglia G., De Souza E.B. Pharmacologic profile of amphetamine derivatives at various brain recognition sites. selective effects on serotonergic systems NIDA Res Monograph. 94:1989;240-258.
3. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 31:1996;444-469.
4. Baumann P., Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother. 6:1995;287-295.
5. Berger U.V., Gu X.F., Azmitia E.C. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol. 215:1992;153-160.
6. Brodkin J., Malyala A., Nash J.F. Effect of acute monoamine depletion on 3,4- methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav. 45:1993;647-653.
7. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiat. 31:1998;80-84.
8. Dittrich A., von Arx S., Staub S. International study on altered states of consciousness (ISASC). Summary of the results. Germ J Psych. 9:1985;319-339.
9. Fahrenberg J., Hampel R., Selg H. Das Freiburger Persönlichkeitsinventar FPI. 1984;Hogrefe, Göttingen.
10. Fitzgerald J.L., Reid J.J. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol. 191:1990;217-220.
11. Gouzoulis-Mayfrank E., Thelen B., Habermeyer E., Kunert H.J., Kovar K.-A., Lindenblatt H., Hermle L., Spitzer M., Sass H. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Psychopharmacology. 142:1999;41-50.
12. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxydmethamphetamine (MDMA or "Ecstasy"). Psychopharmacology. 119:1996;247-260.
13. Gu X.F., Azmitia E.C. Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur J Pharmacol. 235:1993;51-57.
14. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4- methylenedioxymethamphetamine. implications for serotonin-dopamine interactions J Neurochem. 66:1996;243-249.
15. Hegadoren K.M., Baker G.B., Bourin M. 3,4-methylenedioxy analogues of amphetamine. defining the risks to humans Neurosci Biobehav Rev. 23:1999;539-553.
16. Hekmatpanah C.R., Peroutka S.J. 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur J Pharmacol. 177:1990;95-98.
17. Helmlin H.J., Bracher K., Bourquin D., Vonlanthen D., Brenneisen R. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol. 20:1996;432-440.
18. Hyttel J., Arnt J., Sanchez C. The pharmacology of citalopram. Rev Contemp Pharmacother. 6:1995;271-285.
19. Insel T.R., Battaglia G., Johannessen J.N., Marra S., De Souza E.B. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther. 249:1989;713-720.
20. Janke W., Debus G. Die Eigenschaftswörterliste (EWL-K) - Ein Verfahren zur Erfassung der Befindlichkeit. 1978;Göttingen, Hogrefe.
21. Koch S., Galloway M.P. MDMA induced dopamine release in vivo. role of endogenous serotonin J Neural Transm. 104:1997;135-146.
22. Lieberman J.A., Aghajanian G.K. Caveat emptor. Researcher beware Neuropsychopharmacology. 21:1999;471-473.
23. McCann U.D., Hatzidimitriou G., Ricaurte G.A. Prolactin response to fenfluramine is independent of serotonin release. Eur J Pharmacol. 312:1996;R1-R2.
24. McCann U.D., Ricaurte G.A. Reinforcing subjective effects of (+/-) 3,4- methylenedioxymethamphetamine ("Ecstasy") may be separable from its neurotoxic actions. clinical evidence J Clin Psychopharmacol. 13:1993;214-217.
25. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. The Lancet. 352:1998;1433-1437.
26. McKenna D.J., Guan X.-M., Shulgin A.T. 3,4-Methylendioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol Biochem Behav. 38:1991;505-512.
27. Milne R.J., Goa K.L. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 41:1991;450-477.
28. Nash J.F. Ketanserin pretreatment attenuates MDMA induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sciences. 47:1990;2401-2408.
29. Nash J.F., Brodkin J. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release. effect of dopamine uptake inhibitors J Pharmac Exp Ther. 259:1991;820-825.
30. 2C receptors. Neurosci Lett. 177:1994;111-115.
31. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classical hallucinogens. Identification of a new therapeutic class. Entactogens J Psychoactive Drugs. 18:1986;305-313.
32. Nichols D.E., Lloyd D.H., Hoffman A.J., Nichols M.B., Yim G.K. Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. J Med Chem. 25:1982;530-535.
33. Ramamoorthy S., Blakely R.D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science. 285:1999;763-766.
34. Ricaurte G.A., DeLanney L.E., Wiener S.G., Irwin I., Langston J.W. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res. 474:1988;359-363.
35. Rudnick G., Wall S.C. The molecular mechanism of "Ecstasy" [3,4-methylenedioxy methamphetamine (MDMA)] serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A. 89:1992;1817-1821.
36. Sanders-Bush E, Conn PJ (1987): Neurochemistry of serotonin neuronal systems: consquences of serotonin receptor activation. In Meltzer HY (ed), Psychophar-macology: The Third Generation of Progress, New York, Raven Press, pp 95-103.
37. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmac Exp Ther. 240:1987;240-247.
38. Schmidt C.J., Fadayel G.M., Sullivan C.K., Taylor V.L. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function. studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymeth-amphetamine Eur J Pharmacol. 223:1992;65-74.
39. Schmidt C.J., Levin J.A., Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol. 36:1987;747-755.
40. Schmidt C.J., Sullivan C.K., Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem. 62:1994;1382-1389.
41. Sprague J.E., Everman S.L., Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 19:1998;427-441.
42. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol. 36:1987;2297-2303.
43. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y. The demethylenation of methylenedioxymethamphetamine ("Ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 47:1994;1151-1156.
44. Vollenweider F.X., Gamma A., Liechti M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology. 19:1998;241-251. a.
45. Vollenweider F.X., Gamma A., Liechti M., Huber T. Is a single dose MDMA harmless? Neuropsychopharmacology. 21:1999;598-600. a.
46. Vollenweider F.X., Remensberger S., Hell D., Geyer M.A. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology. 143:1999;365-372. b.
47. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F.I., Bäbler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 9:1998;3897-3902. b.
48. White S.R., Obradovic K.M., Wheaton I., Wheaton M.J. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol. 49:1996;455-479.
49. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmac Exp Ther. 273:1995;1063-1070.
50. Yamamoto B.K., Spanos L.J. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol. 148:1988;195-203.